Oberstein, P. E., Hecht, J. R., Raghav, K., Pietrantonio, F., Arnold, D., Moreno, V., Cutsem, E. V., Malik, R. A., Hong, Y. S., Lee, M. A., Su, H. Y., Lee, J., Chandana, S., Cruz-Correa, M., Yuan, Y., Ahmad, A., Lai, K., Hsu, H., Chen, E. X., Elez, E., Lin, C., Lopez, C., Prenen, H., Roselló-Keränen, S., Velez, H., Yeh, Y., Heinemann, V., Eng, C., Beom, S., Tejpar, S., Chowdhury, S., Lyu, X., Kamat, M., Curtin, J. C., Patel, B., Xie, J., Bhattacharya, R., Schnepp, R. W., Yilmaz, E., Iwasawa, R., Daksh, M., Lorenzini, P., Thayu, M., Baig, M., Kim, H. S., Han, S. (2026). Amivantamab Monotherapy in Chemorefractory
                    <i>RAS</i>
                    /
                    <i>BRAF</i>
                    Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02187